Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 12 - 01 tags : Therapeutics save search
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Published: 2022-12-01 (Crawled : 01:00) - biospace.com/
ONCT | $8.97 4.3% 4.12% 4.5K
|
Health Technology
|
| O: 1.47%
H: 2.54%
C: -0.38%
award nasdaq therapeutics
Cidara Therapeutics Announces Issuance of First U.S. Patent for CD388Initial CD388 clinical data expected in the first half of 2023
Published: 2022-12-01 (Crawled : 19:00) - biospace.com/
CDTX | $0.6855 -5.06% -5.32% 350K
|
Health Technology
|
| O: 4.67%
H: 0.0%
C: -2.94%
cd388 patent expected therapeutics
Hoth Therapeutics Announces Submission of Investigational New Drug Application for HT-001
Published: 2022-12-01 (Crawled : 18:00) - biospace.com/
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: 0.49%
H: 9.58%
C: -1.72%
ht-001 drug application therapeutics submission
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope
Published: 2022-12-01 (Crawled : 15:00) - prnewswire.com
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.34%
H: 1.12%
C: 0.05%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.07%
H: 1.06%
C: -0.37%
IMGN | $31.23 0.03% 49M
|
Health Technology
|
| O: -0.39%
H: 3.68%
C: 1.93%
CTIC | $9.09 0.05% 11M
|
Health Technology
|
| O: -0.33%
H: 3.0%
C: -0.33%
research therapeutics cancer ovarian cancer
Compass Therapeutics Announces First Patient Dosed in the Phase 1b CTX-471 Combination Trial with KEYTRUDA® (pembrolizumab)
Published: 2022-12-01 (Crawled : 14:20) - biospace.com/
CMPX | $1.48 -0.67% -0.68% 230K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 14.36%
C: 11.92%
ctx-471 keytruda trial therapeutics phase 2b
ReCode Therapeutics Appoints Trisha Millican to Board of Directors
Published: 2022-12-01 (Crawled : 14:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.56%
H: 0.54%
C: -0.15%
MTCR | $0.5814 -5.14% 84K
|
Health Technology
|
| O: 0.0%
H: 1.21%
C: 0.49%
therapeutics
Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA
Published: 2022-12-01 (Crawled : 14:00) - biospace.com/
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: 0.89%
H: 9.56%
C: 9.03%
fda meeting therapeutics positive vitreoretinal lymphoma
Kintara Therapeutics to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022
Published: 2022-12-01 (Crawled : 14:00) - biospace.com/
KTRA | $0.1204 12.95% 11.46% 7.1M
|
Distribution Services
|
| O: -1.34%
H: 57.34%
C: 34.04%
conference therapeutics growth
Agile Therapeutics To Present At The Upcoming RHK Capital Disruptive Growth Conference
Published: 2022-12-01 (Crawled : 13:20) - globenewswire.com
AGRX | $0.37 0.0% 15K
|
Health Technology
|
| O: -4.76%
H: 4.75%
C: 0.0%
conference therapeutics growth
Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD
Published: 2022-12-01 (Crawled : 13:20) - globenewswire.com
CGTX | $1.86 1.09% 1.08% 120K
|
|
| O: -8.83%
H: 7.81%
C: -18.75%
ct1812 preclinical biomarker trial therapeutics phase 2
Kymera Therapeutics Provides Webcast Information for December 14 Investor Event
Published: 2022-12-01 (Crawled : 13:20) - globenewswire.com
KYMR | $33.965 -3.29% -3.4% 630K
|
Health Technology
|
| O: -1.31%
H: 1.82%
C: 0.42%
therapeutics
BioXcel Therapeutics to Present at Bank of America 2022 Biotech SMID Cap Conference
Published: 2022-12-01 (Crawled : 13:20) - globenewswire.com
BTAI | $2.77 8.63% 7.94% 620K
|
Health Technology
|
| O: 3.26%
H: 12.04%
C: 5.03%
america conference biotech therapeutics
Akari Therapeutics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference
Published: 2022-12-01 (Crawled : 13:20) - globenewswire.com
AKTX | $1.11 -8.26% -9.01% 3.7K
|
Health Technology
|
| O: -0.47%
H: 0.98%
C: -3.64%
conference medical aesthetic therapeutics
CRISPR Therapeutics to Present at the 2022 BMO Growth & ESG Conference
Published: 2022-12-01 (Crawled : 13:20) - globenewswire.com
CRSP M | $55.04 -1.99% -2.03% 1.8M
|
Health Technology
|
| O: -1.11%
H: 2.14%
C: 0.3%
conference crispr esg therapeutics growth
Cidara Therapeutics Announces Issuance of First U.S. Patent for CD388
Published: 2022-12-01 (Crawled : 13:20) - globenewswire.com
CDTX | $0.6855 -5.06% -5.32% 350K
|
Health Technology
|
| O: 4.67%
H: 0.0%
C: -2.94%
cd388 patent therapeutics
TScan Therapeutics Named the Highest-Placed Midsize Biotechnology Company in The Top Places to Work for 2022 by The Boston Globe
Published: 2022-12-01 (Crawled : 13:20) - globenewswire.com
TCRX | News 0 d | $6.79 -1.88% -1.91% 280K
|
Professional, Scientific, and T...
|
| O: -0.93%
H: 9.81%
C: 0.93%
work therapeutics
Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology
Published: 2022-12-01 (Crawled : 13:20) - globenewswire.com
TARA | $2.62 -4.73% -4.96% 210K
|
Health Technology
|
| O: 6.81%
H: 0.07%
C: -9.03%
trials meeting trial therapeutics presentation
Outlook Therapeutics® to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference
Published: 2022-12-01 (Crawled : 13:20) - globenewswire.com
OTLK P | $8.15 -1.69% -1.72% 270K
|
Health Technology
|
| O: 0.0%
H: 1.92%
C: 0.96%
therapeutics conference medical aesthetic
Protagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology Summit
Published: 2022-12-01 (Crawled : 12:20) - prnewswire.com
PTGX | $25.61 1.55% 1.52% 450K
|
Health Technology
|
| O: 0.13%
H: 0.63%
C: -1.52%
therapeutics
Orchard Therapeutics Announces Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel)
Published: 2022-12-01 (Crawled : 12:20) - globenewswire.com
ORTX | $16.7 0.0% 370K
|
Health Technology
|
| O: -0.41%
H: 2.18%
C: -0.11%
libmeldy application therapeutics authorization
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.